<p>CorMedix Inc. (NASDAQ:CRMD - 獲取免費報告) 的股價在週四的午盤交易中上漲了 6.9%。該股最高交易價格為$13.32，最後交易價格為$13.23。在交易中成交了 1,565,066 股，較平均交易量 1,179,993 股增加了 33%。該股此前收盤價為$12.38。</p>
<h2>華爾街分析師觀點</h2>
<p>CRMD 最近成為幾份研究報告的主題。華爾街禪在 4 月 1 日的研究報告中將 CorMedix 的評級從 “賣出” 上調至 “持有”。D. Boral Capital 在 5 月 6 日的研究報告中重申了 “買入” 評級，並對 CorMedix 的股票設定了$15.00 的目標價。加拿大皇家銀行在 3 月 26 日的研究報告中重新發布了 “跑贏大盤” 評級，並對 CorMedix 的股票設定了$12.00 的目標價。Leerink Partners 在 3 月 7 日的研究報告中將 CorMedix 的評級上調至 “強力買入”。最後，Needham &amp; Company LLC 在 5 月 7 日的報告中將 CorMedix 的目標價從$12.00 提高至$15.00，並給予該公司 “買入” 評級。一位股票研究分析師對該股給予了持有評級，六位分析師給予了買入評級，一位分析師給予了強力買入評級。根據 MarketBeat 的數據，該公司目前的平均評級為 “買入”，平均目標價為$15.00。</p>
<p><strong>查看我們最新的 CorMedix 股票報告</strong></p>
<h2>CorMedix 股價上漲 6.5%</h2>
<p>該公司的 50 日移動平均線為$9.52，200 日移動平均線為$9.88。該公司的市值為$893.93 百萬，市盈率為-16.27，貝塔值為 1.54。</p>
<p>CorMedix (NASDAQ:CRMD - 獲取免費報告) 最近在 5 月 6 日發佈了其財報。該公司報告本季度每股收益為$0.30，超出市場共識預期的$0.25，超出$0.05。該公司本季度的收入為$39.08 百萬，而市場共識預期為$38.90 百萬。在去年同期，該公司每股收益為 ($0.25)。股票分析師預測 CorMedix Inc.在當前財政年度將發佈-0.32 的每股收益。</p>
<h2>機構資金流入和流出</h2>
<p>一些對沖基金和其他機構投資者最近增加或減少了對該公司的持股。SBI 證券有限公司在第一季度將其在 CorMedix 的持股增加了 699.7%。SBI 證券有限公司目前擁有 8,685 股該公司的股票，價值$54,000，此前在上個季度又購買了 7,599 股。Janney Montgomery Scott LLC 在第四季度購買了 CorMedix 的新頭寸，價值$81,000。Essex Financial Services Inc.在第一季度購買了價值約$63,000 的 CorMedix 新股份。EntryPoint Capital LLC 在第一季度獲得了價值約$66,000 的 CorMedix 新股份。最後，Captrust Financial Advisors 在第四季度購買了價值約$90,000 的 CorMedix 新頭寸。機構投資者持有該公司 34.18% 的股票。</p>
<h2>關於 CorMedix</h2>
<p>(獲取免費報告)</p>
<p>CorMedix Inc 是一家生物製藥公司，專注於開發和商業化用於預防和治療美國感染性和炎症性疾病的治療產品。其主要產品候選是 DefenCath，一種抗菌導管鎖定溶液，旨在減少腎衰竭成人患者導管相關血流感染的發生率。</p>
<h2>精選故事</h2>
<ul>
<li>我們更看好的五隻股票而非 CorMedix</li>
<li>什麼是債券市場假期？如何投資和交易</li>
<li>Meta 是否在 Libra 失敗多年後策劃穩定幣的迴歸？</li>
<li>為什麼投資高收益股息股票？</li>
<li>白銀的期權火熱：交易者是否在押注突破？</li>
<li>深入瞭解買賣差價</li>
<li>AT&amp;T：這家電信巨頭是買入還是賣出你的投資組合？</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 CorMedix 嗎？</h2>
<p>在你考慮投資 CorMedix 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買...而 CorMedix 並不在名單上。</p>
<p>雖然 CorMedix 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

CRMD

<p>CorMedix Inc.（納斯達克代碼：CRMD）的股價上漲了 6.9%，達到 13.23 美元，交易量增加了 33%。分析師的評級各不相同，其中一位持有評級，六位買入評級和一位強烈買入評級。平均目標價為 15.00 美元。該公司報告每股收益為 0.30 美元，超出預期，收入為 3908 萬美元。機構投資者持有 34.18% 的股份。CorMedix 專注於開發針對傳染病的治療產品，其主要產品為 DefenCath</p>

<p>CorMedix Inc. (NASDAQ:CRMD - Get Free Report)'s share price traded up 6.9% during mid-day trading on Thursday . The stock traded as high as $13.32 and last traded at $13.23. 1,565,066 shares were traded during trading, an increase of 33% from the average session volume of 1,179,993 shares. The stock had previously closed at $12.38.</p>
<div class="lb-trans"><p>CorMedix Inc. (NASDAQ:CRMD - 獲取免費報告) 的股價在週四的午盤交易中上漲了 6.9%。該股最高交易價格為$13.32，最後交易價格為$13.23。在交易中成交了 1,565,066 股，較平均交易量 1,179,993 股增加了 33%。該股此前收盤價為$12.38。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>CRMD has been the subject of several recent research reports. Wall Street Zen raised CorMedix from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note on Tuesday, April 1st. D. Boral Capital reaffirmed a &#34;buy&#34; rating and issued a $15.00 price objective on shares of CorMedix in a research note on Tuesday, May 6th. Royal Bank of Canada reissued an &#34;outperform&#34; rating and set a $12.00 target price on shares of CorMedix in a research report on Wednesday, March 26th. Leerink Partnrs raised CorMedix to a &#34;strong-buy&#34; rating in a research report on Friday, March 7th. Finally, Needham &amp; Company LLC increased their price objective on CorMedix from $12.00 to $15.00 and gave the company a &#34;buy&#34; rating in a report on Wednesday, May 7th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of &#34;Buy&#34; and an average price target of $15.00.</p>
<div class="lb-trans"><p>CRMD 最近成為幾份研究報告的主題。華爾街禪在 4 月 1 日的研究報告中將 CorMedix 的評級從 “賣出” 上調至 “持有”。D. Boral Capital 在 5 月 6 日的研究報告中重申了 “買入” 評級，並對 CorMedix 的股票設定了$15.00 的目標價。加拿大皇家銀行在 3 月 26 日的研究報告中重新發布了 “跑贏大盤” 評級，並對 CorMedix 的股票設定了$12.00 的目標價。Leerink Partners 在 3 月 7 日的研究報告中將 CorMedix 的評級上調至 “強力買入”。最後，Needham &amp; Company LLC 在 5 月 7 日的報告中將 CorMedix 的目標價從$12.00 提高至$15.00，並給予該公司 “買入” 評級。一位股票研究分析師對該股給予了持有評級，六位分析師給予了買入評級，一位分析師給予了強力買入評級。根據 MarketBeat 的數據，該公司目前的平均評級為 “買入”，平均目標價為$15.00。</p>
</div><p><strong>View Our Latest Stock Report on CorMedix</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 CorMedix 股票報告</strong></p>
</div><h2>CorMedix Stock Up 6.5%</h2>
<div class="lb-trans"><h2>CorMedix 股價上漲 6.5%</h2>
</div><p>The business has a 50-day moving average of $9.52 and a two-hundred day moving average of $9.88. The firm has a market capitalization of $893.93 million, a price-to-earnings ratio of -16.27 and a beta of 1.54.</p>
<div class="lb-trans"><p>該公司的 50 日移動平均線為$9.52，200 日移動平均線為$9.88。該公司的市值為$893.93 百萬，市盈率為-16.27，貝塔值為 1.54。</p>
</div><p>CorMedix (NASDAQ:CRMD - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported $0.30 EPS for the quarter, topping the consensus estimate of $0.25 by $0.05. The firm had revenue of $39.08 million during the quarter, compared to the consensus estimate of $38.90 million. During the same period last year, the business earned ($0.25) earnings per share. Equities analysts predict that CorMedix Inc. will post -0.32 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>CorMedix (NASDAQ:CRMD - 獲取免費報告) 最近在 5 月 6 日發佈了其財報。該公司報告本季度每股收益為$0.30，超出市場共識預期的$0.25，超出$0.05。該公司本季度的收入為$39.08 百萬，而市場共識預期為$38.90 百萬。在去年同期，該公司每股收益為 ($0.25)。股票分析師預測 CorMedix Inc.在當前財政年度將發佈-0.32 的每股收益。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. SBI Securities Co. Ltd. raised its holdings in shares of CorMedix by 699.7% in the 1st quarter. SBI Securities Co. Ltd. now owns 8,685 shares of the company's stock worth $54,000 after buying an additional 7,599 shares in the last quarter. Janney Montgomery Scott LLC bought a new position in shares of CorMedix during the fourth quarter valued at $81,000. Essex Financial Services Inc. bought a new stake in shares of CorMedix in the 1st quarter worth about $63,000. EntryPoint Capital LLC acquired a new stake in shares of CorMedix during the 1st quarter worth about $66,000. Finally, Captrust Financial Advisors bought a new position in CorMedix during the 4th quarter valued at about $90,000. Institutional investors own 34.18% of the company's stock.</p>
<div class="lb-trans"><p>一些對沖基金和其他機構投資者最近增加或減少了對該公司的持股。SBI 證券有限公司在第一季度將其在 CorMedix 的持股增加了 699.7%。SBI 證券有限公司目前擁有 8,685 股該公司的股票，價值$54,000，此前在上個季度又購買了 7,599 股。Janney Montgomery Scott LLC 在第四季度購買了 CorMedix 的新頭寸，價值$81,000。Essex Financial Services Inc.在第一季度購買了價值約$63,000 的 CorMedix 新股份。EntryPoint Capital LLC 在第一季度獲得了價值約$66,000 的 CorMedix 新股份。最後，Captrust Financial Advisors 在第四季度購買了價值約$90,000 的 CorMedix 新頭寸。機構投資者持有該公司 34.18% 的股票。</p>
</div><h2>About CorMedix</h2>
<div class="lb-trans"><h2>關於 CorMedix</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.</p>
<div class="lb-trans"><p>CorMedix Inc 是一家生物製藥公司，專注於開發和商業化用於預防和治療美國感染性和炎症性疾病的治療產品。其主要產品候選是 DefenCath，一種抗菌導管鎖定溶液，旨在減少腎衰竭成人患者導管相關血流感染的發生率。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than CorMedix</li>
<li>What is a Bond Market Holiday? How to Invest and Trade</li>
<li>Is Meta Plotting a Stablecoin Comeback Years After Libra's Flop?</li>
<li>Why Invest in High-Yield Dividend Stocks?</li>
<li>Silver's Options Sizzle: Are Traders Betting on a Breakout?</li>
<li>A Deeper Look at Bid-Ask Spreads</li>
<li>AT&amp;T: Is This Telecom Giant a Buy or a Bye for Your Portfolio?</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票而非 CorMedix</li>
<li>什麼是債券市場假期？如何投資和交易</li>
<li>Meta 是否在 Libra 失敗多年後策劃穩定幣的迴歸？</li>
<li>為什麼投資高收益股息股票？</li>
<li>白銀的期權火熱：交易者是否在押注突破？</li>
<li>深入瞭解買賣差價</li>
<li>AT&amp;T：這家電信巨頭是買入還是賣出你的投資組合？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in CorMedix Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 CorMedix 嗎？</h2>
</div><p>Before you consider CorMedix, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮投資 CorMedix 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CorMedix wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買...而 CorMedix 並不在名單上。</p>
</div><p>While CorMedix currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 CorMedix 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

CorMedix (NASDAQ:CRMD) 股價上漲 6.9% - 現在是買入的好時機嗎？